Senseonics Holdings Inc. (NASDAQ: SENS) completed a public offering that raised $92 million through the sale of common stock and pre-funded warrants, the medical technology company announced.

The company sold 10.4 million shares of common stock at $5.00 per share, including 2.4 million additional shares from the full exercise of underwriters' option. Senseonics also sold 8 million pre-funded warrants at $4.999 per share.

TD Cowen and Barclays served as joint book-running managers for the offering, while Mizuho and Lake Street acted as bookrunners. The gross proceeds totaled approximately $92 million before deducting underwriting discounts, commissions and other offering expenses.

Senseonics develops implantable continuous glucose monitoring systems for diabetes patients. The company's products include the Eversense 365 and Eversense E3 systems, which feature sensors inserted under the skin that communicate with external transmitters to send glucose data to smartphone applications every five minutes.

The offering was conducted under a shelf registration statement filed with the Securities and Exchange Commission in August 2025. The registration statement became effective on August 18, 2025.